1. Scrip
  2. >>Business

Regulus Hit As Partner Sanofi Pulls Plug On Kidney Drug Study

Rare Kidney Diseases Proving Difficult For Both Companies

 
• By Andrew McConaghie

Sanofi has abandoned its study of lademirsen in Alport disease, but has not given up on the drug just yet as another indication remains in play.

Sanofi
Sanofi is to halt development against Alport syndrome, but will consider other potential targets. • Source: Shutterstock

Sanofi has decided to abandon development of Regulus Therapeutics’s lademirsen against a rare kidney disease after it failed to show benefit in an interim analysis.

The San Diego-based biotech disclosed in a regulatory filing that Sanofi was ending development of lademirsen (RG-012) for use against...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial